+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are creating a registry to better understand treatment choices and outcomes for pancreatic cancer patients undergoing irreversible electroporation IRE, a type of soft tissue ablation. The study aims to gather evidence to help doctors provide the best care for patients with pancreatic tumors that cannot be surgically removed. This research also seeks to learn about the concerns, limitations, and complications experienced by earlier users of this treatment. The registry collects clinical and pathological data from multiple centers on patients with pancreatic neoplasms who are eligible for soft tissue ablation as determined by their doctors. Data entry is web-based and includes all treatments, follow-ups every 3-4 months in the first year and every 6 months in the second year, for up to two years or until death. Participating institutions submit detailed data and receive annual certificates acknowledging their contribution. Participants provide de-identified information about their treatment and outcomes, monitored for adverse events for up to five years. The registry supports quality assurance by reviewing outcomes and helping centers improve if needed. Researchers focus on adverse events and overall survival, gathering information to improve future ablation treatments for unresectable pancreatic tumors. The study duration allows comprehensive long-term follow-up and data analysis.

Age: 18Years +All Genders
16 locations
E

Actively Recruiting

Researchers are evaluating whether adding renal artery denervation RDN to pulmonary vein isolation PVI improves long-term control of persistent atrial fibrillation AF in patients with controlled or no hypertension. This pilot study builds on prior findings that RDN plus PVI reduced AF recurrence in patients with uncontrolled hypertension. The trial uses implantable loop recorders to closely monitor AF burden, aiming to compare the effectiveness of PVI alone versus PVI combined with RDN. Participants will undergo catheter ablation of all pulmonary veins using cryoballoon energy. Those in the experimental group will receive additional radiofrequency ablation of the renal arteries to reduce cardiac sympathetic nerve activity. The study is randomized and single-blinded, with patients assigned to either PVI alone or PVI plus RDN. The interventions safety, blood pressure effects, nervous system modulation, and impact on quality of life will also be assessed. During the year-long study, participants will have implantable loop recorders placed to continuously track AF episodes. Follow-up visits will measure blood pressure, autonomic function, quality of life, and any adverse effects. Researchers will evaluate AF burden at 12 months as the primary outcome, along with secondary outcomes including procedural complications, emergency visits, hospitalizations, and mortality. The total participation time spans 12 months post-procedure.

Age: 18Years +All GendersPhase Not Applicable
1 location
R

Actively Recruiting

Researchers are evaluating INCB123667 compared to the investigators choice of chemotherapy in women with platinum-resistant ovarian cancer that shows cyclin E1 overexpression. This phase 3, randomized, open-label study aims to assess treatment options for this specific type of ovarian cancer, focusing on progression-free survival and overall survival over up to 2 years. Participants will receive either oral INCB123667 tablets at a dose defined by the study protocol or chemotherapy selected by the investigator according to protocol guidelines. The chemotherapy options are also given at protocol-defined doses. The study compares these two treatment approaches administered in parallel groups. During the trial, participants will be monitored for treatment responses and side effects, with evaluations including tumor measurements according to RECIST criteria and quality of life questionnaires at regular visits for up to 2 years. Safety assessments include tracking adverse events and dose modifications. The study will involve regular visits to assess progression-free survival, overall survival, and other clinical outcomes.

Age: 18Years +FEMALEPhase 3
198 locations